Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022-Reference-Cited by-同舟云学术

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Published:2022-08-18 Issue:33 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Castilla Jesús¹²³^ORCID,Lecea Óscar⁴,Martín Salas Carmen⁵¹,Quílez Delia⁶,Miqueleiz Ana⁵¹,Trobajo-Sanmartín Camino¹²³^ORCID,Navascués Ana⁵¹,Martínez-Baz Iván¹²³^ORCID,Casado Itziar¹²³^ORCID,Burgui Cristina¹²³^ORCID,Egüés Nerea¹²³,Ezpeleta Guillermo³,Ezpeleta Carmen⁵¹

Affiliation:

1. Navarre Institute for Health Research (IdiSNA), Pamplona, Spain

2. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

3. Instituto de Salud Pública de Navarra, Pamplona, Spain

4. Gerencia de Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain

5. Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain

6. Hospital Reina Sofía, Tudela, Spain

Abstract

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference17 articles.

1. Effects of previous infection and vaccination on symptomatic Omicron infections.;Altarawneh;N Engl J Med,2022

2. World Health Organization (WHO). Interim statement on hybrid immunity and increasing population seroprevalence rates. Geneva: WHO; 1 Jun 2022. Available from: https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates

3. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.;Brandal;Euro Surveill,2021

4. Instituto de Salud Pública y Laboral de Navarra. Informe Epidemiológico Semanal 28/2022 (11 al 17 de julio de 2022). [Weekly epidemiological report 28/2022 (11–17 July 2022)]. Pamplona: Instituto de Salud Pública y Laboral de Navarra; 2022. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/3855C06B-B6A2-4E05-BA57-034AB7947A04/481355/InformeEpidemiologicoSemanal28_2022.pdf

5. Centro de Coordinación de Alertas y Emergencias Sanitarias. Variantes de SARS-CoV-2 en España: linaje BA.2.12.1, BA.4 y BA.5 de Ómicron. [SARS-CoV-2 variants in Spain: Omicron lineages BA.2.12.1, BA.4 and BA.5]. Madrid: Ministerio de Sanidad; 2022. Spanish. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/20220628-ERR.pdf

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort;Diseases;2024-08-01

2. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco;Scientific Reports;2024-04-03

3. Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023;Heliyon;2024-04

4. Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study;Vaccines;2024-02-26

5. Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022;Vaccines;2024-01-07